Paul Williams

Dr Paul Williams is a Research Fellow in the Antimicrobial Optimisation Group within the Frazer Institute at The University of Queensland. With more than a decade of experience as an intensive care pharmacist, his research focuses on optimising medicine dosing in critically ill patients through pharmacokinetic/pharmacodynamic (PK/PD) principles, precision dosing, therapeutic drug monitoring, and personalised medicine approaches.

Critically ill patients often experience substantial changes in how medicines are processed by the body, meaning standard dosing approaches may not achieve optimal drug exposures. Paul's research aims to better understand these changes and develop strategies that support safe, effective, and individualised therapy for patients with severe illness.

His research spans antimicrobial optimisation, critical care pharmacotherapy, and clinical dosing studies. Current areas of interest include:

• Antimicrobial and clinical pharmacokinetics/pharmacodynamics (PK/PD)
• Precision dosing and model-informed precision dosing
• Therapeutic drug monitoring (TDM)
• Critical care and intensive care medicine
• Clinical trials and multicentre observational studies
• Personalised medicine and dose individualisation

Paul leads the international DALI-2 study and contributes to several national and international collaborative research programs investigating medicine dosing and outcomes in critically ill patients. His goal is to generate evidence that supports safer and more effective use of medicines in clinical practice and improves outcomes for patients with severe infections and critical illness.

Paul welcomes collaboration with clinicians, researchers, and students interested in critical care pharmacotherapy, precision dosing, and antimicrobial optimisation.